23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic
health and biopharmaceutical company, and the Colorectal Cancer
Alliance (Alliance), the largest nonprofit organization dedicated
to ending colorectal cancer, announced a collaboration to help
advance research on colorectal cancer in the Black/African American
community. The Genetic Insights into Colorectal Cancer in the Black
Community Study is part of 23andMe’s continued efforts to raise
awareness about important health conditions that touch many
individuals but disproportionately impact the Black community.
Through this study, 23andMe and the Alliance aim to recruit
individuals who have African ancestry or identify as Black, African
American, or of African descent who have been diagnosed with
colorectal cancer, which includes colon cancer and cancer of the
rectum.
How colorectal cancer impacts the Black
community
In the United States, Black and African Americans tend to
experience earlier onset and worse disease outcomes for colorectal
cancer. Colorectal cancer is the third most common cancer among men
and women in the Black community. Black Americans have the
second-highest incidence and mortality rates of colorectal cancer
in the U.S. They are 15% more likely to develop colorectal cancer
and 35% more likely to die from it than non-Hispanic white
Americans. Rates of early onset colorectal cancer in the Black
community are also increasing. “At the Alliance, we empower people
to better navigate colorectal cancer outcomes in their lives and
communities,” said Angele Russell, Senior Director of Partnerships
& Health Equity at the Colorectal Cancer Alliance. “This
includes increasing awareness among young Black people who might
not know their risk factors and providing resources aimed at early
detection.”
Addressing the research gap
23andMe offers reports, among which are those based on
statistical models known as polygenic scores (PRS). The PRS reports
are developed by 23andMe scientists and clinical experts using the
company’s database of genetic and self-reported health information
contributed by consented research participants. 23andMe prioritized
colorectal cancer for additional research as it is one of the most
common cancers but has effective screening and preventive lifestyle
factors. However, the new colorectal cancer report is only
available for those of European and Latino/Hispanic descent, as
there is not yet enough data to provide a result for those of other
ethnicities–a historical issue with genetic research and polygenic
scores at large.
“Right now, there’s a gap in research on colorectal cancer in
the Black community,” said Anjali Shastri, Ph.D., Principal Program
Manager at 23andMe, Lead for diversity programs and advocacy
partnerships for research. “We developed this study to help fill in
the gap. Through this study, we hope to improve the polygenic score
and our ability to inform Black and African Americans about how
their genetics impact their chance of developing this
condition.”
Michael Sapienza, Chief Executive Officer at the Colorectal
Cancer Alliance said, “Through this collaboration with 23andMe, we
want to educate the Black community about the importance of knowing
their family history and risk factors to help prevent colorectal
cancer or find it at early stage when it is most treatable.”
How this study can help further research
The Genetic Insights into Colorectal Cancer in the Black
Community Study is recruiting Black and African American
individuals who are 18 years or older, live in the United States,
and have been diagnosed with colorectal cancer.
For those who would like additional information about how to
participate in this research they can learn more on the study
landing page. People who participate in this research study will
have the option to access health reports through a 23andMe+ Premium
membership at no cost.
Those who would like more information about this study can learn
more here. Those interested in learning more about the signs and
symptoms of colorectal cancer and how to get screened today can
learn more here.
About 23andMe
23andMe is a genetics-led consumer healthcare and
biopharmaceutical company empowering a healthier future. For more
information, please visit www.23andMe.com.
About the Colorectal Cancer Alliance
The Colorectal Cancer Alliance empowers a nation of passionate
and determined allies to prevent, treat, and overcome colorectal
cancer in their lives and communities. Founded in 1999 and
headquartered in Washington, D.C., the Alliance advocates for
prevention, magnifies support, and accelerates research. We are the
largest national nonprofit dedicated to colorectal cancer, and we
exist to end this disease in our lifetime. For more information,
visit www.colorectalcancer.org.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including. All statements, other than statements of
historical fact, included or incorporated in this press release are
forward-looking statements. The words "believes," "anticipates,"
"estimates," "plans," "expects," "intends," "may," "could,"
"should," "potential," "likely," "projects," “predicts,”
"continue," "will," “schedule,” and "would" or, in each case, their
negative or other variations or comparable terminology, are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. These
forward-looking statements are predictions based on 23andMe’s
current expectations and projections about future events and
various assumptions. 23andMe cannot guarantee that it will actually
achieve the plans, intentions, or expectations disclosed in its
forward-looking statements and you should not place undue reliance
on 23andMe’s forward-looking statements. These forward-looking
statements involve a number of risks, uncertainties (many of which
are beyond the control of 23andMe), or other assumptions that may
cause actual results or performance to differ materially from those
expressed or implied by these forward-looking statements. The
forward-looking statements contained herein are also subject
generally to other risks and uncertainties that are described from
time to time in the Company’s filings with the Securities and
Exchange Commission, including under Item 1A, “Risk Factors” in the
Company’s most recent Annual Report on Form 10-K, as filed with the
Securities and Exchange Commission, and as revised and updated by
our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
The statements made herein are made as of the date of this press
release and, except as may be required by law, 23andMe undertakes
no obligation to update them, whether as a result of new
information, developments, or otherwise.
Contacts
23andMe: Media: press@23andMe.comInvestors:
investors@23andMe.com
Colorectal Cancer Alliance: Media:
eblasi@CCAlliance.org
23andMe (NASDAQ:ME)
過去 株価チャート
から 8 2024 まで 9 2024
23andMe (NASDAQ:ME)
過去 株価チャート
から 9 2023 まで 9 2024